Limited information is available regarding the histology of
hepatitis C virus infection in children. The aim of this study was
to determine the histological pattern of chronic hepatitis C (CHC)
in children, and liver biopsy specimens from 109 pediatric patients
with CHC were examined. Each biopsy specimen was evaluated based on
a numerical scoring system for the stage of fibrosis (1-4), the
grade of portal/periportal necroinflammation (0-4), the grade of
lobular necroinflammation (0-4), and their sum (final grade). The
histological lesions considered to be characteristic of chronic
hepatitis were also evaluated. None of the children had liver
cirrhosis, and 105 cases (97%) were stage 1 or 2. Only 4 children
were stage 3. Two of these 4 cases showed hemosiderosis. A
significant correlation was observed between the staging score and
the final grade in the pediatric patients (r = .59; P < .0001).
The histological characteristics of adult CHC, such as lymphoid
aggregate, bile duct injury, and fatty changes, were also observed
in the children. In conclusion, the majority of children with CHC
presented with mild fibrosis, but a few showed CHC with lobular
distortion and hemosiderosis. Frequent blood transfusion may
aggravate hepatic lesions in pediatric CHC.
Hepatitis C Genotype Guides Health Plans
Because the suggested treatment length and success rates vary between genotypes, this is typically one of the first distinctions made after a Hepatitis C diagnosis. In order to assure the correct course of therapy is approved, health insurance companies are...
Math May Foretell Hepatitis C Drug Success
By doing a math formula calculation on the specific genetics of an individual's Hepatitis C infection, doctors may be able to predict whether or not treatment will be successful....
Treatment Approved for Kids With Hepatitis C
Instead of prescribing the drugs for "off-label use," pediatricians can now feel more confident when treating children with Hepatitis C. Schering-Plough's Rebetol and PEG-Intron have been officially approved by the FDA for treating Hepatitis C in kids aged 3 to...